title: PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting.
abstract: OBJECTIVE
  Drug targeting to the CNS is challenging due to the presence of blood-brain barrier. We investigated chitosan (Cs) nanoparticles (NPs) as drug transporter system across the blood-brain barrier, based on mAb OX26 modified Cs.
  
  
  METHODS
  Cs NPs functionalized with PEG, modified and unmodified with OX26 (Cs-PEG-OX26) were prepared and chemico-physically characterized. These NPs were administered (intraperitoneal) in mice to define their ability to reach the brain.
  
  
  RESULTS
  Brain uptake of OX26-conjugated NPs is much higher than of unmodified NPs, because: long-circulating abilities (conferred by PEG), interaction between cationic Cs and brain endothelium negative charges and OX26 TfR receptor affinity.
  
  
  CONCLUSIONS
  Cs-PEG-OX26 NPs are promising drug delivery system to the CNS.
authors.affiliation: Grupo de Investigación Ciencia de los Materiales, Instituto de Química, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia, Calle 70 N° 52-21, Medellín, Colombia.
authors.forename: Yuliana
authors.initials: Y
authors.lastname: Monsalve
authors.affiliation: Pharmaceutical Technology, Te.Far.T.I. group, Department of Life Sciences, University of Modena & Reggio Emilia, Via Campi 183,41124 Modena, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Tosi
authors.affiliation: Pharmaceutical Technology, Te.Far.T.I. group, Department of Life Sciences, University of Modena & Reggio Emilia, Via Campi 183,41124 Modena, Italy.
authors.forename: Barbara
authors.initials: B
authors.lastname: Ruozi
authors.affiliation: Pharmaceutical Technology, Te.Far.T.I. group, Department of Life Sciences, University of Modena & Reggio Emilia, Via Campi 183,41124 Modena, Italy.
authors.forename: Daniela
authors.initials: D
authors.lastname: Belletti
authors.affiliation: Department of Biomedical, Metabolic & Neural Sciences, University of Modena & Reggio Emilia, Via Campi 213, 41124 Modena, Italy.
authors.forename: Antonietta
authors.initials: A
authors.lastname: Vilella
authors.affiliation: Department of Biomedical, Metabolic & Neural Sciences, University of Modena & Reggio Emilia, Via Campi 213, 41124 Modena, Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Zoli
authors.affiliation: Pharmaceutical Technology, Te.Far.T.I. group, Department of Life Sciences, University of Modena & Reggio Emilia, Via Campi 183,41124 Modena, Italy.
authors.forename: Maria Angela
authors.initials: MA
authors.lastname: Vandelli
authors.affiliation: Pharmaceutical Technology, Te.Far.T.I. group, Department of Life Sciences, University of Modena & Reggio Emilia, Via Campi 183,41124 Modena, Italy.
authors.forename: Flavio
authors.initials: F
authors.lastname: Forni
authors.affiliation: Grupo de Investigación Ciencia de los Materiales, Instituto de Química, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia, Calle 70 N° 52-21, Medellín, Colombia.
authors.forename: Betty L
authors.initials: BL
authors.lastname: López
authors.affiliation: Grupo de Investigación Ciencia de los Materiales, Instituto de Química, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia, Calle 70 N° 52-21, Medellín, Colombia.
authors.forename: Ligia
authors.initials: L
authors.lastname: Sierra
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000737:chemistry; D001812:Blood-Brain Barrier / Q000187:drug effects; D001921:Brain / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects*; D048271:Chitosan / Q000008:administration & dosage* / Q000009:adverse effects; D016503:Drug Delivery Systems; D006801:Humans; D051379:Mice; D053758:Nanoparticles / Q000008:administration & dosage* / Q000009:adverse effects; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000911:Antibodies, Monoclonal; D011092:Polyethylene Glycols; D048271:Chitosan
keywords: blood–brain barrier; chitosan; drug targeting; monoclonal antibody OX26; nanoparticles